Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

NCT07844213 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

NCT NCT07844213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Completed
Start date
August 25, 2022
Completion date
August 31, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital heart disease, pulmonary hypertension